Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights Nkarta (Nasdaq: NKTX) reported fourth-quarter and full-year 2025 results and clinical progress on March 25, 2026. The company had $295.1 million of cash and investments as of December 31, 2025, which it says will fund operations into 2029. Dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7 (12 billion cells per cycle). Initial clinical data from Ntrust-1 and Ntrust-2 are targeted for presentation at a medical conference in 2026. Full-year R&D was $90.4 million and net loss was $104.1 million (or $1.41 per share).

#NKTX Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights

www.stocktitan.net/news/NKTX/nkarta-reports...

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights  Nkarta (NASDAQ:NKTX) reported third-quarter 2025 results and clinical progress for its NKX019 autoimmune program on Nov 10, 2025. Key points: $316.5 million cash and investments at Sept 30, 2025, expected to fund operations into 2029; enrollment began in the second dose-escalation cohort after a combined iDSMB cleared simultaneous dosing across Ntrust-1 and Ntrust-2; modified lymphodepletion with fludarabine plus cyclophosphamide produced complete B-cell depletion in treated patients versus partial depletion with cyclophosphamide alone. Initial NKX019 data are planned for a medical conference in 2026.

#NKTX Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights 

www.stocktitan.net/news/NKTX/nkarta-reports...

Nkarta's $334M Cash Runway Extends to 2029 as Autoimmune Treatment Trials Advance Biotech company reports strong financial position with $334M in cash, extending operations to 2029. Anticipates crucial autoimmune treatment trial results in H2 2025. Get insights.

#NKTX Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

www.stocktitan.net/news/NKTX/nkarta-reports...

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights Nkarta (NKTX) reported its Q1 2025 financial results and corporate updates. The company holds a strong cash position of $351.9 million, expected to fund operations into 2029. Key highlights include ongoing enrollment in multiple clinical trials for NKX019, including the Ntrust-1 trial (expanded to include primary membranous nephropathy), Ntrust-2 trial, and investigator-sponsored trials for myasthenia gravis and systemic lupus erythematosus. The company modified its lymphodepletion regimen across platforms to include both fludarabine and cyclophosphamide. Initial clinical data from Ntrust trials is expected in H2 2025. Financially, Nkarta reported a Q1 net loss of $32.0 million ($0.43 per share) and implemented a restructuring plan reducing workforce by 34% to extend cash runway.

#NKTX Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

www.stocktitan.net/news/NKTX/nkarta-reports...

BREAKING NEWS: ( NASDAQ: #NKTX ) Expected US Company Earnings on Thursday, March 27th, 2025

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights Nkarta (NKTX) reported its Q4 and full year 2024 financial results, announcing a significant restructuring including a 34% workforce reduction (53 positions) to extend cash runway. The company ended 2024 with a cash balance of $380.5 million, now expected to fund operations into 2029.For FY2024, Nkarta reported a net loss of $108.8 million ($1.60 per share), with R&D expenses of $96.7 million and G&A expenses of $31.5 million. The restructuring is expected to cost $5.5-6.5 million in cash payments.The company's development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in autoimmune conditions. Initial data from the Ntrust-1 and Ntrust-2 trials is expected in H2 2025. The executive leadership team will be reduced by over 50% as part of the restructuring efforts.

#NKTX Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

www.stocktitan.net/news/NKTX/nkarta-reports...

🚨 Institutions #optionsvolume surge detected!

Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #NKTX 924.0x
2. #INFY 356.0x
3. #LTRX 40.0x
4. #MAMA 40.0x
5. #GCI 36.2x

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#DTE, #NVCR, #MITK, #ALGM, #NKTX

#OptionFlow #OptionsTrading #Trading

Nkarta Expands NKX019 Cell Therapy Trial to 4 New Autoimmune Diseases, Breakthrough Treatment Protocol Unveiled | NKTX Stock News Nkarta advances NKX019 CAR NK-cell therapy with new trials for systemic sclerosis, myositis, and other autoimmune conditions. Treatment aims for long-term remission through B-cell depletion.

#NKTX Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

#investing #StockMarket #stocks

www.stocktitan.net/news/NKTX/nkarta-announc...

#NKTX Nkarta to Participate in an Upcoming Investor Conference

www.stocktitan.net/news/NKTX/nkarta-to-part...

Just In: ( NASDAQ: #NKTX ) Strong Buy Recommendation Issued On NKTX By Raymond James

#StockMarket #News

News; ( NASDAQ: #NKTX ) Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

#StockMarket #News